Instructions for composition and sensitivity
Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS 2 ) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
1 . A method for treating a disease or disorder in or around an eye of an individual in need thereof, the method comprising:
administering a therapeutically effective amount of a pharmaceutical composition to an ocular surface, surrounding ocular tissues, or a combination thereof of the individual;
wherein the pharmaceutical composition comprises a therapeutically effective amount of selenium disulfide (SeS 2 ); and
wherein the pharmaceutical composition is administered at bedtime or within an hour of bedtime.
2 . The method of claim 1 , wherein the disease or disorder in or around the eye is dry eye syndrome.
3 . The method of claim 2 , wherein the individual has meibomian gland dysfunction (MGD).
4 . The method of claim 3 , wherein the pharmaceutical composition is administered at bedtime.
5 . The method of claim 4 , wherein the pharmaceutical composition is applied to an eyelid margin of the individual.
6 . The method of claim 5 , wherein the pharmaceutical composition is administered to the individual in a volume of less than about microliters (μL).
7 . The method of claim 1 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual.
8 . The method of claim 1 , wherein the pharmaceutical composition comprises selenium disulfide in a therapeutically effective concentration.
9 . The method of claim 8 , wherein the therapeutically effective concentration is about 0.5 by weight (wt. %).
10 . The method of claim 9 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual.
11 . The method of claim 10 , wherein the disease or disorder in or around the eye of the individual in need thereof is dry eye syndrome and the individual has MGD.
12 . The method of claim 1 , wherein the disease or disorder in or around the eye is meibomian gland dysfunction (MGD).
13 . The method of claim 1 , wherein the disease or disorder in or around the eye is meibomian gland dysfunction (MGD) and the individual has signs and symptoms of dry eye disease.
14 . The method of claim 13 , wherein the pharmaceutical composition is applied to an eyelid of the individual.
15 . The method of claim 14 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual at bedtime.
16 . The method of claim 15 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.
17 . The method of claim 1 , wherein the individual has signs and symptoms of dry eye disease.
18 . The method of claim 1 , wherein the individual has meibomian gland dysfunction (MGD).
19 . The method of claim 1 , wherein the individual has meibomian gland dysfunction (MGD) and sins and symptoms of dry eye disease.
20 . The method of claim 18 , wherein the pharmaceutical composition is applied to an eyelid of the individual.
21 . The method of claim 20 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual at bedtime.
22 . The method of claim 18 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.
23 . The method of claim 1 , wherein the pharmaceutical composition is applied to an eyelid of the individual.
24 . The method of claim 23 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to the eyelid of the individual.
25 . The method of claim 24 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.
26 . The method of claim 1 , wherein the pharmaceutical composition is administered to the individual in a volume of less than about 25 microliters (μL) at bedtime.
27 . The method of claim 26 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 wt. %.
28 . The method of claim 27 , wherein the individual applies the pharmaceutical composition to an eyelid margin of the individual.
29 . The method of claim 1 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.
30 . The method of claim 29 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 wt. %.
31 . The method of claim 30 , wherein the pharmaceutical composition the individual applies a volume of less than about 25 μL of the pharmaceutical composition.
32 . The method of claim 31 , wherein the pharmaceutical composition is applied to an eyelid margin of the individual at bedtime.